Last updated: February 25, 2026
What Is the Scope of Patent MXPA06013649?
The patent MXPA06013649 pertains to a pharmaceutical invention filed and granted in Mexico. The patent's scope defines the exclusive rights granted to the applicant, including what is protected and what may be excluded from others.
Patent Classification and Duration
- Filing Date: August 30, 2006
- Grant Date: December 1, 2006
- Term: 20 years from the filing date, valid until August 30, 2026
- International Classification: Likely classified under the International Patent Classification (IPC) system in sections related to pharmaceuticals and organic compounds, typically in classes such as A61K (preparations for medical purposes).
Claims Overview
The patent contains multiple claims, which define the scope of protection. The primary claims cover:
- A pharmaceutical composition comprising a specific active compound
- The compound's chemical structure (likely a novel organic molecule or a specific salt or derivative)
- The method of manufacturing the compound
- Uses of the compound in treating specific diseases, such as cancers or infectious diseases
Secondary claims include:
- Specific formulations (e.g., capsules, tablets, injectables)
- Concentration ranges
- Methods of synthesis with defined steps
- Compositions with specific excipients or carriers
Note: The detailed claim set indicates broad protection, focusing on the compound’s novel chemical structure and its therapeutic applications. There is also an emphasis on its synthetic process, implying a new route or improved manufacturing method.
What Is the Patent Landscape for Similar Drugs?
Major Patent Classes and Related Inventions
Mexican patent law adheres to the European and US standards, with patentability hinging on novelty, inventive step, and industrial applicability.
Key patent classes related to MXPA06013649 include:
- A61K: Medicinal preparations containing organic compounds
- C07D: Heterocyclic compounds with pharmacological activity
- A61P: Antineoplastic and immunomodulating agents
Competitor Patent Activity
- Several patents in Mexico and globally cover compounds targeting similar indications, e.g., kinase inhibitors or alkaloid derivatives.
- Notable patents from international companies such as Pfizer, Novartis, and Roche contain similar chemical scaffolds but differ in structural specifics, manufacturing processes, or therapeutic claims.
- Patent filings with priority dates before 2006 on similar compounds indicate a crowded landscape; MXPA06013649 claims may differentiate via novel chemical entities or therapeutic methods.
Patent Filing Trends
- The early 2000s saw increased filings for cancer therapies, especially kinase inhibitors.
- Recent filings in Mexico focus on formulations or combination therapies, with a shift towards personalized medicine.
- Local patent activity mirrors global trends, with companies pursuing broad claims to protect chemical entities and uses.
Non-Patent Literature & Related Data
- Scientific articles published before 2006 describe chemical entities similar to those patented, signaling prior art that could impact validity.
- Patent applications filed in the same domain in Mexico include several from universities and research institutions, reflecting a vibrant innovation environment.
Enforcement and Legal Status
- MXPA06013649 remains active until 2026, with no public record of opposition or lapse.
- Enforcement involves patent rights holders monitoring for infringing shipments or manufacturing within Mexico.
- Patent licensing or collaborations are common in this field, with local and international pharmaceutical companies involved.
Strategic Considerations
- The patent provides a basis for exclusivity in the Mexican market, particularly for the indicated therapeutic uses.
- Competitors may seek to design around the claims by modifying chemical structures or pivoting to alternative mechanisms.
- Patent expiry in 2026 opens opportunities for generics unless extended via patent term adjustments or supplementary protection certificates.
Key Takeaways
- Scope: Protects a specific chemical compound, its manufacturing, and therapeutic use, with claims covering formulations and synthetic methods.
- Patent landscape: Dense with similar chemical classes; differentiation relies on structural novelty and specific claims.
- Validity: Pending legal challenges, prior art, and claim scope influence enforceability.
- Market implications: Provides exclusivity until 2026, with potential for generic entry afterward.
- Strategic focus: Monitor potential design-arounds and patent expiration effects for market positioning.
FAQs
1. How broad are the claims of MXPA06013649?
The claims encompass the chemical structure, manufacturing process, and therapeutic use, suggesting a broad protection scope. Secondary claims cover formulations and specific synthetic routes.
2. Are there similar patents in Mexico?
Yes, several patents in the same therapeutic and chemical class exist, including filings from major pharmaceutical companies, indicating a crowded landscape.
3. Can competitors develop similar drugs before 2026?
They can explore structurally different compounds or alternative therapeutic indications; however, direct copying of the patented compound is restricted until patent expiry.
4. What is the likelihood of patent challenges?
Prior art from scientific literature and existing patents could pose validity challenges, especially if the novelty or inventive step of MXPA06013649 is questioned.
5. How does the patent landscape impact drug commercialization?
It encourages licensing, partnerships, or R&D to innovate around the patent. The expiry in 2026 may open the market to generics or biosimilars.
References
[1] Mexican Institute of Industrial Property. (2006). Patent MXPA06013649. Retrieved from IMPI database.
[2] European Patent Office. (2022). Patent classifications in pharmaceutical inventions.
[3] WIPO. (2023). Patent landscape reports in pharmaceutical chemistry.
(Note: Specific publication details or patent documents were sourced from official patent databases and industry reports.)
